Ophthalmic Drugs

Ophthalmic Drugs Market by Dispense Type (Over the Counter, Prescription), Disease Condition (Allergy, Dry Eye Disorder, Glaucoma), Products, Dosage Form, Distribution - Global Forecast 2024-2030

360iResearch Analyst
SPEAK TO ANALYST? OR FACE-TO-FACE MEETING?
Want to know more about the ophthalmic drugs market or any specific requirement? Ketan helps you find what you're looking for.
DOWNLOAD A FREE PDF
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.

[196 Pages Report] The Ophthalmic Drugs Market size was estimated at USD 28.99 billion in 2023 and expected to reach USD 30.56 billion in 2024, at a CAGR 5.86% to reach USD 43.21 billion by 2030.

Ophthalmic Drugs Market
To learn more about this report, request a free PDF copy

An ophthalmic drug is a medication used to treat eye diseases, disorders, or injuries. These medications can be administered in various ways including topical application, injection into the eye, and systemic administration. The most common type of ophthalmic drugs are antibiotics, anti-inflammatory agents, and glaucoma medications. There is an increasing demand for treatments that target specific eye conditions or diseases, such as glaucoma and age-related macular degeneration creating requirements for effective ophthalmic drugs. However, the cost and time intensive R&D process and possible side effects of drugs may create obstacles for the market growth. Moreover, the development of gene therapy for treating eye diseases has observed significant growth over the past few years, with a number of promising treatments currently being tested and developed. New advancements in AI-based technology have enabled ophthalmic drug manufacturers to improve accuracy and efficiency when it comes to drug delivery and diagnosis.

Ophthalmic Drugs Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
Regional Insights

The Americas ophthalmic drugs market has observed significant growth in recent years due to the high prevalence of eye-related diseases, the emergence of innovative products such as biologics and biosimilars, and an increase in elderly population requiring eye treatments. Market trends indicate that spending on ophthalmic drugs is expected to continue to increase over the coming years. Furthermore, a growing number of international OTC brands are entering the market, diversifying product offerings. The ophthalmic drugs market in the Asia-Pacific is highly diverse, with various countries having different levels of healthcare investment, improving healthcare infrastructure, and product availability. The market has experienced strong growth year-over-year due to large-scale population countries and increased need for eye care products in the region. Factors such as rising incomes and improved access to healthcare have made ophthalmic drugs more accessible to consumers in the Asia-Pacific. The growing number of clinical trials in Europe for new drug developments contributes to the market growth in the EMEA region. In addition, factors such as increasing sales of branded medications and a rise in R&D investments in ophthalmic drugs are expected to provide significant opportunities for market players across the EMEA region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Ophthalmic Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Ophthalmic Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • Bausch + Lomb Plans to Acquire XIIDRA

    Bausch + Lomb has recently announced an agreement to acquire XIIDRA, a dry eye treatment, in the context of ophthalmic drugs. This acquisition is expected to fortify Bausch + Lomb's pharmaceutical product portfolio by incorporating a branded prescription treatment option. With the acquisition, Bausch + Lomb reaffirms its dedication to offering healthcare professionals comprehensive solutions to fulfill the unique requirements of their patients. [Published On: 2023-06-30]

  • FDA Approves Novaliq’s Cyclosporine Ophthalmic Solution For Treatment Of Dry Eye Disease

    Novaliq GmbH received approval from the U.S. Food and Drug Administration (FDA) for Cyclosporine Ophthalmic Solution for treating Dry Eye Disease. This topical formulation of cyclosporine is unique as it does not require dilution before use. The approval was based on the successful outcomes of the Phase 3 clinical trial, which indicated considerable improvements in the signs and symptoms of dry eye disease after a two-week treatment period. This medication is specifically indicated for adults with moderate to severe dry eye disease and can be used twice everyday or as directed by a healthcare professional. [Published On: 2023-06-08]

  • Eyenovia and Formosa Partner For New Ophthalmic Therapeutics

    Eyenovia and Formosa Ophthalmic Therapeutics formed a partnership to jointly develop advanced ophthalmic drug delivery technologies. This collaboration combines Eyenovia's cutting-edge Optejet dispensing technology with Formosa's advanced APNT nanoparticle formulation platform, allowing for the precise delivery of topical therapies. This collaboration aims to explore the potential expansion of the development pipeline. [Published On: 2023-02-16]

Key Company Profiles

The report delves into recent significant developments in the Ophthalmic Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alcon Vision LLC, Allergan PLC by AbbVie Inc., Apotex Inc., Bausch Health Companies Inc., Bayer AG, Carl Zeiss AG, Coherus Biosciences, Inc., EyePoint Pharmaceuticals, Inc., Eyevensys, Genentech, Inc., Johnson & Johnson Service, Inc., Kodiak Sciences Inc., Lupin Limited, Merck & Co., Nicox SA, Novaliq GmbH, Novartis AG, Ocular Therapeutix, Inc., OCuSOFT Inc., Pfizer Inc., Recipharm AB, Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd., Somerset Pharma, LLC., Sun Pharmaceutical Industries, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Ophthalmic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Dispense Type
    • Over the Counter
    • Prescription
  • Disease Condition
    • Allergy
    • Dry Eye Disorder
    • Glaucoma
    • Retinal Disorder
      • Diabetic Retinopathy
      • Dry Age-related Macular Degeneration
      • Wet Age-related Macular Degeneration
  • Products
    • Capsules & Tablets
    • Drops
    • Gels
    • Ointments
    • Solutions & Suspensions
  • Dosage Form
    • Liquid Ophthalmic Drug Forms
    • Multicompartment Drug Delivery Systems
    • Semisolid Ophthalmic Drug Forms
    • Solid Ophthalmic Drug Forms
  • Distribution
    • Drug Stores
    • Hospital Pharmacies
    • Online Pharmacies

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Ophthalmic Drugs Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Ophthalmic Drugs Market?
  3. What are the technology trends and regulatory frameworks in the Ophthalmic Drugs Market?
  4. What is the market share of the leading vendors in the Ophthalmic Drugs Market?
  5. Which modes and strategic moves are suitable for entering the Ophthalmic Drugs Market?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Ophthalmic Drugs Market, by Dispense Type
  7. Ophthalmic Drugs Market, by Disease Condition
  8. Ophthalmic Drugs Market, by Products
  9. Ophthalmic Drugs Market, by Dosage Form
  10. Ophthalmic Drugs Market, by Distribution
  11. Americas Ophthalmic Drugs Market
  12. Asia-Pacific Ophthalmic Drugs Market
  13. Europe, Middle East & Africa Ophthalmic Drugs Market
  14. Competitive Landscape
  15. Competitive Portfolio
  16. List of Figures [Total: 26]
  17. List of Tables [Total: 562]
  18. List of Companies Mentioned [Total: 30]
Frequently Asked Questions
  1. How big is the Ophthalmic Drugs Market?
    Ans. The Global Ophthalmic Drugs Market size was estimated at USD 28.99 billion in 2023 and expected to reach USD 30.56 billion in 2024.
  2. What is the Ophthalmic Drugs Market growth?
    Ans. The Global Ophthalmic Drugs Market to grow USD 43.21 billion by 2030, at a CAGR of 5.86%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.